What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders

Simply Wall St.02-02 21:11

Terns Pharmaceuticals previously announced an amendment to its Exclusive Option and License Agreement with Hansoh, converting a non-exclusive license into an exclusive, sublicensable, royalty-bearing,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608860598?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-02-02 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608860598","market":"nz","top_or_hot":-1,"title":"What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Terns Pharmaceuticals previously announced an amendment to its Exclusive Option and License Agreement with Hansoh, converting a non-exclusive license into an exclusive, sublicensable, royalty-bearing,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/what-terns-pharmaceuticals-terns-expanded-global-rights-to-t\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-02 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/what-terns-pharmaceuticals-terns-expanded-global-rights-to-t><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Terns Pharmaceuticals previously announced an amendment to its Exclusive Option and License Agreement with Hansoh, converting a non-exclusive license into an exclusive, sublicensable, royalty-bearing,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/what-terns-pharmaceuticals-terns-expanded-global-rights-to-t\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TERN.AU","symbol_name":"Terracom Ltd","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/what-terns-pharmaceuticals-terns-expanded-global-rights-to-t","article_id":"2608860598","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/what-terns-pharmaceuticals-terns-expanded-global-rights-to-t","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608860598","pubTimestamp":1770037913,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Terns Pharmaceuticals previously announced an amendment to its Exclusive Option and License Agreement with Hansoh, converting a non-exclusive license into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license for TERN-701 outside China, Taiwan, Hong Kong, and Macau.\nThis move materially increases Terns’ control over the global development and commercialization path of TERN-701, reshaping the asset’s long-term commercial potential.\nNext, we’ll examine how gaining an...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TERN.AU":"Terracom Ltd","BK7083":"煤与消费用燃料","TERN":"Terns Pharmaceuticals, Inc.","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"Terns Pharmaceuticals(TERN)扩大TERN-701的全球权利对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN.AU":1.5,"TERN":1.5},"content_text":"Terns Pharmaceuticals previously announced an amendment to its Exclusive Option and License Agreement with Hansoh, converting a non-exclusive license into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license for TERN-701 outside China, Taiwan, Hong Kong, and Macau. This move materially increases Terns’ control over the global development and commercialization path of TERN-701, reshaping the asset’s long-term commercial potential. Next, we’ll examine how gaining an exclusive worldwide license for TERN-701 outside key Asian territories influences Terns’ investment narrative. AI is about to change healthcare. These 111 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementWhat Is Terns Pharmaceuticals' Investment Narrative?The core Terns Pharmaceuticals story still rests on whether TERN-701 and the broader pipeline can justify today’s valuation, given zero revenue and consistent losses. Investors are effectively backing clinical execution, future partnering and the company’s ability to manage dilution after a very large follow-on raise and a significant lock-up expiry in early 2026. Against that backdrop, the new exclusive, sublicensable worldwide license for TERN-701 outside China, Taiwan, Hong Kong and Macau looks material for the near term: it tightens Terns’ grip on its lead asset just as interim Phase 1 data attracted more attention and a higher analyst price target. That shift slightly tilts the balance of short term catalysts toward clinical data and potential business development, but it does not remove the key risk that continued cash burn and share issuance remain central to the story. However, the coming lock-up expiry could change the trading picture in ways investors should understand.\n\nOur valuation report unveils the possibility Terns Pharmaceuticals' shares may be trading at a premium.Exploring Other PerspectivesTERN 1-Year Stock Price Chart Two fair value estimates from the Simply Wall St Community span roughly US$58 to US$99 per share, showing how differently private investors view Terns’ upside. Set that against the company’s lack of revenue, ongoing losses above US$90 million, and the heightened importance of upcoming TERN-701 data after the expanded license, and it is clear you are weighing very different views on how the story could play out. Exploring several of these perspectives can help frame your own expectations around both risk and potential rewards.Explore 2 other fair value estimates on Terns Pharmaceuticals - why the stock might be worth just $58.12!Build Your Own Terns Pharmaceuticals NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Terns Pharmaceuticals research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.Our free Terns Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Terns Pharmaceuticals' overall financial health at a glance.No Opportunity In Terns Pharmaceuticals?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Terns Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608860598","isCrawlerRequest":true}